Amiodarone

• Description:

  Amiodarone is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC50 of 19.1 μM.

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  Autophagy; Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Membrane Transporter/Ion Channel

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Amiodarone.html

• Purity:

  98.32

• Solubility:

  DMSO : ≥ 175 mg/mL

• Smiles:

  CCCCC1=C(C(C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)=O)C3=C(O1)C=CC=C3

• Molecular Formula:

  C25H29I2NO3

• Molecular Weight:

  645.31

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Singh, B.N. and E.M. Vaughan Williams, The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol, 1970. 39 (4) : p. 657-67.|[2]Rosenbaum, M.B., et al., Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol, 1976. 38 (7) : p. 934-44.|[3]Wilson BD, et al. Amiodarone-induced pulmonary toxicity in the rat. Lung. 1989;167 (5) :301-11.|[4]Plomp TA, et al. Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration. In Vivo. 1987 Sep-Oct;1 (5) :265-79.|[5]Takai S, et al. Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. J Appl Toxicol. 2016 Jan;36 (1) :35-47.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Biochem Biophys Res Commun. 2020 Feb 19;522 (4) :862-868.|Biotechnol Bioeng. 2021 Dec;118 (12) :4687-4698.|Cell. 2022 Dec 8;185 (25) :4801-4810.e13.|Cell. 2023 Nov 22;186 (24) :5363-5374.e16.|Cell. 2025 May 29;188 (11) :3013-3029.e19.|Ecotoxicol Environ Saf. 2021 Apr 1:212:111991.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|Patent. US20180263995A1.|SSRN. 2023 Nov 8.|Cell. 2025 May 29;188 (11) :3013-3029.e19.|Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Viruses. 2021 Jun 28;13 (7) :1255.

• CAS Number:

  [1951-25-3]